
Global Targeted RNA Sequencing Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Targeted RNA Sequencing market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Targeted RNA Sequencing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Targeted RNA Sequencing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Targeted RNA Sequencing market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Targeted RNA Sequencing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Targeted RNA Sequencing market include Thermo Fisher, Berry Genomics, Roche Holdings, Macrogen, LabCorp, Illumina, GENEWIZ, Eurofins and BGI, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Targeted RNA Sequencing, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Targeted RNA Sequencing, also provides the value of main regions and countries. Of the upcoming market potential for Targeted RNA Sequencing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Targeted RNA Sequencing revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Targeted RNA Sequencing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Targeted RNA Sequencing company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Targeted RNA Sequencing Segment by Company
Thermo Fisher
Berry Genomics
Roche Holdings
Macrogen
LabCorp
Illumina
GENEWIZ
Eurofins
BGI
Targeted RNA Sequencing Segment by Type
Amplicon Sequencing
Enrichment Sequencing
Exome Sequencing
Targeted RNA Sequencing Segment by Application
Diagnostic Lab
Hospitals & Clinics
Research Institutes
Biotechnology Company
Targeted RNA Sequencing Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Targeted RNA Sequencing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Targeted RNA Sequencing key companies, revenue, market share, and recent developments.
3. To split the Targeted RNA Sequencing breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Targeted RNA Sequencing market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Targeted RNA Sequencing significant trends, drivers, influence factors in global and regions.
6. To analyze Targeted RNA Sequencing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted RNA Sequencing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted RNA Sequencing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted RNA Sequencing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeted RNA Sequencing industry.
Chapter 3: Detailed analysis of Targeted RNA Sequencing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Targeted RNA Sequencing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Targeted RNA Sequencing in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Targeted RNA Sequencing market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Targeted RNA Sequencing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Targeted RNA Sequencing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Targeted RNA Sequencing market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Targeted RNA Sequencing is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Targeted RNA Sequencing market include Thermo Fisher, Berry Genomics, Roche Holdings, Macrogen, LabCorp, Illumina, GENEWIZ, Eurofins and BGI, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Targeted RNA Sequencing, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Targeted RNA Sequencing, also provides the value of main regions and countries. Of the upcoming market potential for Targeted RNA Sequencing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Targeted RNA Sequencing revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Targeted RNA Sequencing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Targeted RNA Sequencing company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Targeted RNA Sequencing Segment by Company
Thermo Fisher
Berry Genomics
Roche Holdings
Macrogen
LabCorp
Illumina
GENEWIZ
Eurofins
BGI
Targeted RNA Sequencing Segment by Type
Amplicon Sequencing
Enrichment Sequencing
Exome Sequencing
Targeted RNA Sequencing Segment by Application
Diagnostic Lab
Hospitals & Clinics
Research Institutes
Biotechnology Company
Targeted RNA Sequencing Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Targeted RNA Sequencing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Targeted RNA Sequencing key companies, revenue, market share, and recent developments.
3. To split the Targeted RNA Sequencing breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Targeted RNA Sequencing market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Targeted RNA Sequencing significant trends, drivers, influence factors in global and regions.
6. To analyze Targeted RNA Sequencing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted RNA Sequencing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted RNA Sequencing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted RNA Sequencing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeted RNA Sequencing industry.
Chapter 3: Detailed analysis of Targeted RNA Sequencing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Targeted RNA Sequencing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Targeted RNA Sequencing in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Targeted RNA Sequencing Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Targeted RNA Sequencing Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Targeted RNA Sequencing Market Dynamics
- 2.1 Targeted RNA Sequencing Industry Trends
- 2.2 Targeted RNA Sequencing Industry Drivers
- 2.3 Targeted RNA Sequencing Industry Opportunities and Challenges
- 2.4 Targeted RNA Sequencing Industry Restraints
- 3 Targeted RNA Sequencing Market by Company
- 3.1 Global Targeted RNA Sequencing Company Revenue Ranking in 2024
- 3.2 Global Targeted RNA Sequencing Revenue by Company (2020-2025)
- 3.3 Global Targeted RNA Sequencing Company Ranking (2023-2025)
- 3.4 Global Targeted RNA Sequencing Company Manufacturing Base and Headquarters
- 3.5 Global Targeted RNA Sequencing Company Product Type and Application
- 3.6 Global Targeted RNA Sequencing Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Targeted RNA Sequencing Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Targeted RNA Sequencing Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Targeted RNA Sequencing Market by Type
- 4.1 Targeted RNA Sequencing Type Introduction
- 4.1.1 Amplicon Sequencing
- 4.1.2 Enrichment Sequencing
- 4.1.3 Exome Sequencing
- 4.2 Global Targeted RNA Sequencing Sales Value by Type
- 4.2.1 Global Targeted RNA Sequencing Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Targeted RNA Sequencing Sales Value by Type (2020-2031)
- 4.2.3 Global Targeted RNA Sequencing Sales Value Share by Type (2020-2031)
- 5 Targeted RNA Sequencing Market by Application
- 5.1 Targeted RNA Sequencing Application Introduction
- 5.1.1 Diagnostic Lab
- 5.1.2 Hospitals & Clinics
- 5.1.3 Research Institutes
- 5.1.4 Biotechnology Company
- 5.2 Global Targeted RNA Sequencing Sales Value by Application
- 5.2.1 Global Targeted RNA Sequencing Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Targeted RNA Sequencing Sales Value by Application (2020-2031)
- 5.2.3 Global Targeted RNA Sequencing Sales Value Share by Application (2020-2031)
- 6 Targeted RNA Sequencing Regional Value Analysis
- 6.1 Global Targeted RNA Sequencing Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Targeted RNA Sequencing Sales Value by Region (2020-2031)
- 6.2.1 Global Targeted RNA Sequencing Sales Value by Region: 2020-2025
- 6.2.2 Global Targeted RNA Sequencing Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Targeted RNA Sequencing Sales Value (2020-2031)
- 6.3.2 North America Targeted RNA Sequencing Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Targeted RNA Sequencing Sales Value (2020-2031)
- 6.4.2 Europe Targeted RNA Sequencing Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Targeted RNA Sequencing Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Targeted RNA Sequencing Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Targeted RNA Sequencing Sales Value (2020-2031)
- 6.6.2 South America Targeted RNA Sequencing Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Targeted RNA Sequencing Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Targeted RNA Sequencing Sales Value Share by Country, 2024 VS 2031
- 7 Targeted RNA Sequencing Country-level Value Analysis
- 7.1 Global Targeted RNA Sequencing Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Targeted RNA Sequencing Sales Value by Country (2020-2031)
- 7.2.1 Global Targeted RNA Sequencing Sales Value by Country (2020-2025)
- 7.2.2 Global Targeted RNA Sequencing Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.7.2 France Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.14.2 China Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.17.2 India Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Targeted RNA Sequencing Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Targeted RNA Sequencing Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Targeted RNA Sequencing Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Thermo Fisher
- 8.1.1 Thermo Fisher Comapny Information
- 8.1.2 Thermo Fisher Business Overview
- 8.1.3 Thermo Fisher Targeted RNA Sequencing Revenue and Gross Margin (2020-2025)
- 8.1.4 Thermo Fisher Targeted RNA Sequencing Product Portfolio
- 8.1.5 Thermo Fisher Recent Developments
- 8.2 Berry Genomics
- 8.2.1 Berry Genomics Comapny Information
- 8.2.2 Berry Genomics Business Overview
- 8.2.3 Berry Genomics Targeted RNA Sequencing Revenue and Gross Margin (2020-2025)
- 8.2.4 Berry Genomics Targeted RNA Sequencing Product Portfolio
- 8.2.5 Berry Genomics Recent Developments
- 8.3 Roche Holdings
- 8.3.1 Roche Holdings Comapny Information
- 8.3.2 Roche Holdings Business Overview
- 8.3.3 Roche Holdings Targeted RNA Sequencing Revenue and Gross Margin (2020-2025)
- 8.3.4 Roche Holdings Targeted RNA Sequencing Product Portfolio
- 8.3.5 Roche Holdings Recent Developments
- 8.4 Macrogen
- 8.4.1 Macrogen Comapny Information
- 8.4.2 Macrogen Business Overview
- 8.4.3 Macrogen Targeted RNA Sequencing Revenue and Gross Margin (2020-2025)
- 8.4.4 Macrogen Targeted RNA Sequencing Product Portfolio
- 8.4.5 Macrogen Recent Developments
- 8.5 LabCorp
- 8.5.1 LabCorp Comapny Information
- 8.5.2 LabCorp Business Overview
- 8.5.3 LabCorp Targeted RNA Sequencing Revenue and Gross Margin (2020-2025)
- 8.5.4 LabCorp Targeted RNA Sequencing Product Portfolio
- 8.5.5 LabCorp Recent Developments
- 8.6 Illumina
- 8.6.1 Illumina Comapny Information
- 8.6.2 Illumina Business Overview
- 8.6.3 Illumina Targeted RNA Sequencing Revenue and Gross Margin (2020-2025)
- 8.6.4 Illumina Targeted RNA Sequencing Product Portfolio
- 8.6.5 Illumina Recent Developments
- 8.7 GENEWIZ
- 8.7.1 GENEWIZ Comapny Information
- 8.7.2 GENEWIZ Business Overview
- 8.7.3 GENEWIZ Targeted RNA Sequencing Revenue and Gross Margin (2020-2025)
- 8.7.4 GENEWIZ Targeted RNA Sequencing Product Portfolio
- 8.7.5 GENEWIZ Recent Developments
- 8.8 Eurofins
- 8.8.1 Eurofins Comapny Information
- 8.8.2 Eurofins Business Overview
- 8.8.3 Eurofins Targeted RNA Sequencing Revenue and Gross Margin (2020-2025)
- 8.8.4 Eurofins Targeted RNA Sequencing Product Portfolio
- 8.8.5 Eurofins Recent Developments
- 8.9 BGI
- 8.9.1 BGI Comapny Information
- 8.9.2 BGI Business Overview
- 8.9.3 BGI Targeted RNA Sequencing Revenue and Gross Margin (2020-2025)
- 8.9.4 BGI Targeted RNA Sequencing Product Portfolio
- 8.9.5 BGI Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.